BioCurex, Inc.(fka BOCX)

[bocxman]

regarding the lung cancer study i just posted (which I hope everyone has already read many times over and is not seeing it for the first time now), it is clear that the procedures and statistical methods used to come up with the results are SOUND. the only question marks are with regard to the SAMPLE SET itself..for example:

1) they say "there was no comparison with samples from patients with other pulmonary diseases" (question: is it a truly representative sample?)

2) they do not say where and how they obtained the samples (question: is it a truly blind sample?)

NOW...if I read that study on it's own, with BOCX having ZERO CREDIBILITY, I would say: "looks very good, but there are a lot of questions"

BUT...with Abbott having completed blind sample verification, I can be much more confident in the data believing that Abbott's due diligene process is truly blind and representative. Clearly, though, there are no certainties unless something is actually PUBLISHED that convinces the shareholders and the market that RECAF performs well on a large, blind, and representative sample.